阿托伐他汀对急性冠状动脉综合征介入患者血清ox-LDL、hs-CRP及slCAM-1水平以及心功能的影响

目的:探讨阿托伐他汀对急性冠状动脉综合征(ACS)介入患者血清氧化低密度脂蛋白(ox-LDL)、高敏C反应蛋白(hs-CPR)及可溶性细胞间黏附分子-1(slCAM-1)水平以及心功能的影响。方法:选取2015年2月-2016年4月在我院接受治疗的ACS患者120例作为研究对象,采用乱数表法将所有患者分为观察组和对照组,两组均60例。在常规治疗基础上,观察组患者给予大剂量阿托伐他汀口服,对照组给予小剂量阿托伐他汀口服,对比两组患者治疗前后ox-LDL、hs-CRP及slCAM-1水平以及治疗后的心功能指标,观察两组患者治疗后的不良反应。结果:两组患者治疗2周后ox-LDL、hs-CRP及slCAM-1较治疗前均有明显下降,且观察组治疗2周后ox-LDL、hs-CRP及slCAM-1明显低于对照组(P0.05)。治疗2周后观察组的E峰与A峰流速比值(E/A)、左心室射血分数(LVEF)均显著高于对照组,而收缩指数、舒张指数和Tei指数均显著低于对照组(P0.05)。两组患者均未出现严重不良反应。结论:大剂量阿托伐他汀治疗ACS介入患者能有效降低患者术后ox-LDL、hs-CRP及slCAM-1ACS水平,抑制炎症反应,改善患者心功能,药物安全性与小剂量相当,值得临床推广应用。

Effect of Atorvastatin on Serum Levels of ox-LDL, hs-CRP and slCAM-1 and Cardiac Function in Patients with Acute Coronary Syndrome

ABSTRACT Objective: To investigate the effects of atorvastatin on serum oxidized low density lipoprotein (ox-LDL), high sensitive C reactive protein (hs-CPR) and soluble intercellular adhesion molecule -1 (slCAM-1) level and heart function in patients with acute coronary syndrome (ACS). Methods: A total of 120 patients with ACS, who were treated in Dongfang Hospital of Beijing University of Chinese Medicine from February 2015 to April 2016, were selected and randomly divided into observation group(n=60) and control group(n=60). On the basis of routine treatment, the patients in the observation group were given high dose of atorvastatin, and the control group was given low dose of atorvastatin orally. The levels of ox-LDL, hs-CRP and slCAM-1 before and after treatment, the indexes of cardiac function after treatment in the two groups were compared; and the adverse reactions after treatment in the two groups were ob- served. Results: The levels of ox-LDL and hs-CRP and slCAM-1 in the two groups after 2 weeks of treatment were significantly lower than those before treatment, and the levels of ox-LDL, hs-CRP and slCAM-1 in the observation group after 2 weeks of treatment were significantly lower than those in the control group (P<0.05). The E peak and A peak velocity ratio (E/A) and left ventricular ejection frac- tion (LVEF) of the observation group were significantly higher than those of the control group after 2 weeks of treatment, while the con- traction index,diastolic index and myocardial work index were significantly lower than the control group (P<0.05). There were no serious adverse reactions in the two groups. Conclusion: High dose of atorvastatin for interventional patients with ACS can effectively reduce the levels of ox-LDL, hs-CRP and slCAM-1ACS after operation, inhibite inflammatory reaction and improve cardiac function, and drug safety is comparable to low dose, which is worthy of clinical application.